
CONTENTS

USER'S GUIDE TO THE CURRICULUM

Background.....	11
Rationale Underlying the Pedagogy	11
Organization.....	13
How to Use the Seminar Modules	14
Consultation	17

<u>ACKNOWLEDGEMENTS</u>	18
--------------------------------------	----

<u>REFERENCES & RELATED ARTICLES</u>	19
---	----

<u>CONTRIBUTORS</u>	21
----------------------------------	----

CURRICULUM & TEACHING MATERIALS

PART I: INTRODUCTION TO THE ASCP'S MODEL CURRICULUM

PREFACE.....	30
Using the Model Curriculum to Teach Psychiatric Residents, Medical Students, Primary Care Physicians and Other Health Professionals.....	32
RATIONALE.....	33
ORGANIZATION OF A PSYCHOPHARMACOLOGY PROGRAM.....	33
Relationship of Research to Training	34

PART II: THE CORE CURRICULUM

OVERVIEW AND EDUCATIONAL OBJECTIVES	35
Knowledge.....	35
Skills	36
WHAT AND HOW TO TEACH.....	39
The Didactic Program	39
Organization of Courses and Presentations	39
Special Considerations Related to Presentations	40
• Issues, Concepts and a Template.....	43
• Specific Seminar Topics.....	46

• Teaching Sessions on Psychosocial Topics.....	54
Literature Review Seminar	56
Case Conference	59
Computers and Psychopharmacology.....	60
• General	60
• Research	61
• Organizations.....	61
• Smartphones	61
Supervision	62
• Introduction	62
• Background.....	63
• Rationale.....	63
• Clinical Mentorship Teaching Using Selected Case Material	66
• Supervision in Psychopharmacology Clinics, Inpatient Units and Emergency Rooms.....	68
Off-Label Prescribing	68
Reading Materials	69
• Textbooks	69
• Journals and Newsletters	69
Neuroscience Seminar Series.....	72
Psychopharmacology Units	73
HOW TO EVALUATE	75
Formal Examination.....	75
Documentation Patterns	76
Evaluation by Supervisor.....	78
Trainee Evaluation of Supervision and of the Program.....	79
Accreditation Issues	79
FINAL PEARLS.....	79
Professionalism.....	80
<u>PART III: CURRICULA FOR SPECIAL AREAS</u>	
CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY.....	81

Child and Adolescent Seminar Series.....	82
Child and Adolescent Instruments and Rating Scales	83
GERIATRIC PSYCHOPHARMACOLOGY.....	84
Geriatric Seminar Series	85
ALCOHOL AND SUBSTANCE USE PSYCHOPHARMACOLOGY	86
Alcohol and Substance Use Seminar Series	86

PART IV: APPENDICES

APPENDIX A: Objective Assessment Measures: Rating Scales	87
APPENDIX B: List of Other Useful Books	97
APPENDIX C: List of Additional Journals	100
APPENDIX D: Forms for Evaluation of Trainee, Clinical Supervisor, Teaching Faculty, and Of Entire Course.....	102
APPENDIX E: An Investigative Psychiatry Curriculum for Residents	116
APPENDIX F: Guidelines for Pharmacotherapy Follow Up Visits and Quality of Care	120
APPENDIX G: Psychopharmacology and the Internet	124

SEMINAR COURSES AND AUTHORS

<u>Crash Course – David Osser, M.D.</u>	Seminar Number
<u>Antipsychotics</u>	101
▪ David N. Osser, M.D.	
<u>Medicine for Bipolar Disorder</u>	102
▪ Theo Manschreck, M.D., MPH, James W. Jefferson, M.D.	
<u>Antidepressants</u>	103
▪ David N. Osser, M.D.	
<u>Anti-Anxiety Agents</u>	104
▪ David N. Osser, M.D.	
<u>Drug-Drug Interactions 101 + Table (105 B)</u>	105
▪ Jessica R. Oesterheld, M.D., David N. Osser, M.D., Mujeeb Shad, M.D.	
<u>Long-Term Psychopharmacology</u>	106
▪ Ira Glick, M.D., James M. Ellison, M.D., MPH	
<u>Art of Psychopharmacology</u>	107
▪ Ira D. Glick, M.D., Richard Balon, M.D.	
 <u>Basic Course</u>	
<u>Psychopharmacology in the Emergency Room</u>	201
▪ Michael D. Jibson, M.D., Ph.D.	
<u>Pharmacokinetics of Psychotropic Drugs</u>	202
▪ Terence A. Ketter, M.D.	
<u>Schizophrenia and Antipsychotic Medications: Focus on Acute Treatment</u>	203
▪ Michael D. Jibson, M.D., Ph.D, Ira Glick, M.D.	
<u>Acute Mania</u>	204
▪ Terence A. Ketter, M.D.	
<u>Bipolar Disorders Psychopathology</u>	205
▪ Po W. Wang, M.D.	
<u>Bipolar Disorders Acute Treatment</u>	206
▪ Po W. Wang, M.D.	
<u>Antidepressant Pharmacotherapy</u>	207
▪ Charles DeBattista, M.D.	
<u>Treatment Resistant Depression</u>	208
▪ Charles DeBattista, M.D.	
<u>Electroconvulsive Therapy</u>	209
▪ Justin Coffey, M.D.	

<u>Substance Use Disorders</u>	210
▪ Jyothsna Karlapalem, M.D., Mujeeb Shad, M.D.	
<u>Evaluation and Treatment of Sleep Disorders</u>	211
▪ Rafael Pelayo, M.D.	
<u>Psychopharmacology of Violence</u>	212
▪ Leslie Citrome, M.D., MPH	
<u>Traumatic Brain Injury</u>	213
▪ Jonathan M. Silver, M.D.	

Advanced Course

<u>Combining Pharmacotherapy and Psychotherapy</u>	301
▪ Ira D. Glick, M.D., Matej Markota, M.D.	
<u>Mood Disorders in Women of Child Bearing Age</u>	302
▪ Katherine E. Williams, M.D.	
<u>Pregnancy and Psychopharmacology</u>	303
▪ Marlene Freeman, M.D.	
<u>Schizophrenia and Antipsychotic Medications: Mid/Long-Term Treatment</u>	304
▪ Ira D. Glick, M.D.	
<u>Panic Disorder</u>	305
▪ Lorrin Koran, M.D., R. Bruce Lydiard, Ph.D., M.D.	
<u>Generalized Anxiety Disorder</u>	306
▪ Lorrin Koran, M.D., R. Bruce Lydiard, Ph.D., M.D.	
<u>Social Anxiety Disorder/Social Phobia</u>	307
▪ R. Bruce Lydiard, Ph.D., M.D., James Ellison, M.D., MPH, Lorrin Koran, M.D.	
<u>Post-Traumatic Stress Disorder</u>	308
▪ Thomas A. Mellman, M.D., R. Bruce Lydiard, Ph.D., M.D., Howard A. Fenn, M.D.	
<u>Personality Disorders</u>	309
▪ Donald W. Black, M.D., Lawrence J. Siever, M.D. Mujeeb Shad, M.D.	
<u>Eating Disorders</u>	310
▪ B. Timothy Walsh, M.D.	
<u>Body Dysmorphic Disorder</u>	311
▪ Katharine A. Phillips, M.D.	
<u>Psychopharmacology and the HIV-Positive Patient</u>	312
▪ Lawrence M. McGlynn, M.D., Peter Marcus, PsyD.	

SEMINAR MODULES : COURSES (CONT.)

Seminars Which Can Be Included In Any Course or May Be Optional

<u>Quality Psychiatric Care: Accurate Diagnosis & Measurement-Based Care</u>	401
▪ David V. Sheehan, M.D.	
<u>Evidence Based Medicine and Psychopharmacology</u>	402
▪ Leslie Citrome, M.D., James M. Ellison, M.D.	
<u>Therapeutic Drug Monitoring in Psychopharmacology</u>	403
▪ Georgios Schoretsanitis, M.D.	
<u>Neuromodulation in Psychiatry</u>	404
▪ Alexander Bystritsky, M.D.	
<u>When and How to use Clozapine</u>	405
▪ David N. Osser, M.D.	
<u>Tardive Dyskinesia</u>	406
▪ Christoph Correll M.D., Jose M Rubio M.D., John Kane M.D., Yash Joshi, M.D.	
<u>Short Term Interventions with Potentially Long-Term Benefits in MDD</u>	407
▪ Charles DeBattista, M.D.	
<u>Lithium</u>	408
▪ David N. Osser, M.D.	
<u>A Brief History of Benzodiazepines</u>	409
▪ Carl Salzman, M.D.	
<u>Herbal Psychopharmacology</u>	410
▪ James W. Jefferson, M.D. (deceased)	
<u>Psychopharmacologic Treatment of Aggressive/Self Injurious Intellectually Disabled Adult...</u>	411
▪ David S. Janowsky, M.D.	
<u>Adult ADHD</u>	412
▪ David Goodman, M.D.	
<u>Suicidal Behavior and Psychopharmacology</u>	413
▪ J. John Mann, M.D.	
<u>Sexual Function/Dysfunction, Physiology, Diagnosis and Prevalence</u>	414
▪ Anita H. Clayton, M.D.	
<u>Factors Affecting Sexual Functioning and Management of Sexual Dysfunction</u>	415
▪ Anita H. Clayton, M.D., David Wilson, M.D.	
<u>Cross-Cultural Psychopharmacology</u>	416
▪ Weiguo Zhu, M.D., Ph.D	
<u>Clinical Ethnopsychopharmacology</u>	417

▪ Andrew Olagunju, M.D., William B. Lawson, M.D., Ph.D.	
<u>Evaluating the Psychopharmacology Research Literature</u>	418
▪ Srinath Gopinath, M.D.	
<u>Ethical Issues in Psychopharmacology</u>	419
▪ Thomas Gutheil, M.D., Yash Joshi, M.D., Ph.D.	
<u>Psychopharmacology in Medically Complex Patients</u>	420
▪ Angela Mayorga, M.D., FAPA	
<u>Forensic Aspects of Psychopharmacology</u>	421
▪ William Cardasis, M.D., Brandon G Moore, M.D., MBA	
<u>An Ethical Framework for Clinicians and Psychopharmacology Industry Interactions</u> ..	422
▪ Michael D. Jibson, M.D.	
<u>Deconstructing Drug Company Promotion</u>	423
▪ Jeff Mattes, M.D.	
<u>Clinical Psychopharmacology Trials</u>	424
▪ John M. Kane, M.D., Thomas Laughren, M.D., Lawrence Alphas, M.D., Mujeeb Shad, M.D.,	

Child and Adolescent Psychopharmacology – Vishal Madaan, M.D.

<u>Pediatric Psychopharmacology: General Principles</u>	501
▪ Shashank Joshi, M.D., Kiki Chang, M.D.	
<u>Update on Child and Adolescent Psychopharmacology</u>	502
▪ Glen R. Elliot, M.D., Ph.D.	
<u>Neuropsychopharmacology Basics and Beyond</u>	503
▪ Mani Pavuluri, M.D., Ph.D., Mujeeb Shad, M.D.	
<u>Teamwork: The Therapeutic Alliance in Pediatric Psychopharmacology</u>	504
▪ Shashank V. Joshi, M.D, FAAP	
<u>Using and Teaching Evidence-Based Medicine in Child Psychiatry</u>	505
▪ Vishal Madaan, M.D.	
<u>Psychopharmacology of Autism Spectrum Disorder</u>	506
▪ Christopher J. McDougle, M.D., Robyn P. Thom, M.D.	
<u>The Assessment and Treatment of ADHD</u>	507
▪ Shashank V. Joshi, M.D., FAAP	
<u>Childhood Onset Schizophrenia: Evaluation and Treatment</u>	508
▪ Janani Venugopalakrishnan, M.D. MPH, David Braitman, M.D., Philip Cawkwell, M.D.	
<u>Antipsychotic Adverse Effects in Children and Adolescents</u>	509

▪ Christoph U. Correll, M.D.	
<u>Emerging Issues in the Treatment of Impulsive Aggression In Children/Adolescents</u> ...	510
▪ Peter S. Jensen, M.D.	
<u>An Overview of Pediatric Depression</u>	511
▪ Cynthia R. Pfeffer, M.D.	
<u>The Use of Medications for Pediatric Bipolar Disorder</u>	512
▪ Kiki D. Chang, M.D.	
<u>Treatment of Childhood and Adolescents with Anxiety Disorders</u>	513
▪ John Walkup, M.D.	
<u>Childhood OCD</u>	514
▪ Vishal Madaan, M.D., Kate Fitzgerald, M.D., Jenny Lee, M.D.	
<u>Post-Traumatic Stress Disorder in Youth</u>	515
▪ Vishal Madaan, M.D., Venkata Kolli, MRCPsych	
<u>Tourette’s Disorder</u>	516
▪ Vishal Madaan, M.D., Isheeta Zalpuri, M.D.	
<u>FDA Approved Psychotropic Medications for Pediatric Use</u>	517
▪ Vishal Madaan, M.D., Boris Lorberg, M.D., Yana Turkowski, M.D.	
<u>Geropsychiatry Psychopharmacology – James Ellison, M.D.</u>	
<u>Pharmacotherapy and Alzheimer’s Disease</u>	601
▪ Gary W. Small, James H. Ellison, M.D., MPH	
<u>Delirium</u>	602
▪ Barbara Kamholz, M.D., Howard Fenn, M.D.	
<u>Psychosis and Schizophrenia in Later Life</u>	603
▪ David Sultzer, M.D., Brandon C. Yarns, M.D.	
<u>Major Neurocognitive Disorder with Behavioral Disturbance (Behavioral and Psychological Symptoms of Dementia (BPSD))</u>	604
▪ Howard H. Fenn, M.D., Rita Hitching, MSc	
<u>Depression in the Elderly</u>	605
▪ Gary W. Small, M.D., James M. Ellison, M.D., MPH	
<u>Bipolar Disorders in Late Life</u>	606
▪ Robert C. Young, M.D., Benoit H. Mulsant, M.D.; Dr. Soham Rej, M.D.	
<u>Anxiety Disorders in Later Life</u>	607
▪ Jennifer Gatchel, M.D.	
<u>Alcohol and Sedative-Hypnotic Addiction in the Elderly</u>	608
▪ David W. Oslin, M.D.	
<u>Drug-Drug Interactions in the Elderly</u>	609

-
- Bruce G. Pollock, M.D., Ph.D.

Alcohol and Substance Use Psychopharmacology – Charles O’Brien, M.D.

<u>Brain and Behavior: Substance Use</u>	701
▪ Charles P. O’Brien, M.D., Ph.D., Charles Dackis, M.D.	
<u>Addiction: A Disease of the Brain</u>	702
▪ Charles P. O’Brien, M.D., Ph.D.	
<u>Substance Use: The Nation’s Number One Health Problem</u>	703
▪ James Cornish, M.D., Charles P. O’Brien, M.D.	
<u>Marijuana in Mental Health</u>	704
▪ Joe Pierre, M.D.	
<u>Stimulants</u>	705
▪ Charles Dackis, M.D.	
<u>Nicotine: A Drug of Abuse</u>	706
▪ Janet Audrain-McGovern, Ph.D.	
<u>Alcoholism</u>	707
▪ David W. Oslin, M.D.	
<u>Hallucinogenic Agents</u>	708
▪ Laura F. McNicholas, M.D., Ph.D.	
<u>Prescription Drug Use</u>	709
▪ Kyle M. Kampman, M.D.	
<u>Psychiatric Disorders and Psychotherapy of Substance Abuse</u>	710
▪ Robert M. Weinrieb, M.D.	
<u>Effects of Drugs on the Developing Brain: Pregnancy, Adolescence and Beyond</u>	711
▪ Marina Goldman, M.D.	
<u>Medical Complications of Substance Abuse</u>	712
▪ Phil Green, M.D., Vishal Madaan, M.D.	
<u>Pain and Opioids</u>	713
▪ Charles O’Brien, M.D.	

Algorithms – David Osser, M.D.

<u>Advantages and Disadvantages</u>	801
▪ David N. Osser, M.D.	
<u>Major Depression</u>	802
▪ David N. Osser, M.D., Christoforos Iraklis Giakoumatos, M.D.	
<u>Bipolar Depression</u>	803
▪ David N. Osser, M.D.	

<u>Bipolar Mania</u>	804
▪ David N. Osser, M.D., Dana Wang, M.D.	
<u>Psychotic Depression</u>	805
▪ David N. Osser, M.D., OM. Mohammed, M.D.	
<u>PTSD</u>	806
▪ David N. Osser, M.D.	
<u>Schizophrenia</u>	807
▪ David N. Osser, M.D., Mohsen Jalali Roudsari, M.D., Theo C. Manschreck, M.D., Yash Joshi, M.D.	
<u>Social Anxiety Disorder</u>	808
▪ David N. Osser, M.D.	
<u>Generalized Anxiety Disorder</u>	809
▪ David N. Osser, M.D., Harmony Abejuela, M.D.	